<?xml version="1.0" encoding="UTF-8"?>
<ack id="ack0010">
 <title>Acknowledgments</title>
 <p>We thank S. Rubin and H. Golding for their insightful review of the manuscript. We thank NIBSC (D. Wilkinson) for providing the clinical samples as part of a WHO study. Source materials for the WHO study were donated by Teresa Lambe, Sarah Gilbert, Adrian Hill, and Katie Ewer (Jenner Institute, University of Oxford, UK); Annie Winkler (Emory University, USA); Scott Koepsell (University of Nebraska); Arne Brantsaeter, Richard Olaussen, Unni Bergerud (Oslo University Hospital); Sheila MacLennan, Alex Barber (National Health Service Blood and Transplant, Leeds, UK), and Calum Semple (University of Liverpool, UK). The antibody characterization work described in this manuscript was supported by US Food and Drug Administration (
  <funding-source id="gs1">FDA)</funding-source> Office of Counterterrorism and Emerging Threats (OCET) - Medical Countermeasures initiative (MCMi) OCET 2019-1018 funds to S.K. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government.
 </p>
 <sec id="sec6">
  <title>Author Contributions</title>
  <p id="p0150">Designed research: S.K.; Performed research – S.F., S.R., E.M.C., L.K, and S.K.; Contributed to Writing – S.K.</p>
 </sec>
 <sec sec-type="COI-statement" id="sec7">
  <title>Declaration of Interests</title>
  <p id="p0155">The authors have declared that no competing interests exist. The GFPDL technology and Ebola peptides described in this study are covered by US patents.</p>
 </sec>
</ack>
